Brazil’s Center for Technological Development in Health of the Oswaldo Cruz Foundation (CDTS/Fiocruz) and the European Infrastructure for Translational Medicine (Eatris) have signed a letter of intent with the goal of promoting initiatives in translational sciences.
The partnership includes not only education and training projects within this theme, but also the creation of a Global Hub of Drug Repositioning, with an initial focus on neglected and rare diseases. Following the invitation by Eatris, the CDTS/Fiocruz will also be part of the Translation Together international consortium, an initiative involving both public and private institutions that work in the field.
“Eatris is one of the world’s largest translational science organizations. It is a network consisting of 110 research institutions spread over 13 European countries. This partnership has great potential to generate cooperation projects, not only for the CDTS, but for Fiocruz as a whole. It is a fundamental phase to consolidate practices of translational science in the institution,” explains Marco Túlio de Barros e Castro, lawyer of the Innovation Office of CDTS/Fiocruz.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze